Physician profile
Asad Nasir
NPI 1346446721
$9,729.72
in general payments reported to CMS, 2019-2025
36 companies · $3,203 in 2025
The $3,203 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $286 · 2021: $440 · 2022: $724 · 2023: $952 · 2024: $2,644 · 2025: $3,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,855 · Travel and Lodging: $788 · Education: $117 · Consulting Fee: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,854.81 |
| Travel and Lodging | $788.22 |
| Education | $116.71 |
| Consulting Fee | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,827.99 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,569.44 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Pulmonx Corporation | $1,295.08 | 2023-2024 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $891.02 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $763.76 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $668.10 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $298.09 | 2022-2025 | Tezspire, Tavneos |
| Mylan Specialty L.P. | $295.61 | 2019-2024 | Yupelri, Yupelri |
| Genzyme Corporation | $283.49 | 2019-2025 | |
| Insmed, INC. | $232.08 | 2019-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $228.64 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Lilly USA, LLC | $223.04 | 2025 | Zepbound |
| Electromed, INC. | $179.32 | 2024-2025 | Smartvest |
| Verona Pharma, INC. | $124.67 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $81.94 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $67.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.34 | 2021-2024 | Glassia |
| Astellas Pharma US INC | $66.16 | 2025 | Cresemba |
| Mallinckrodt Enterprises LLC | $65.40 | 2019 | |
| Philips North America LLC | $49.43 | 2019-2020 | |
| Inspire Medical Systems, INC. | $48.85 | 2024-2025 | Inspire |
| Vapotherm INC | $40.82 | 2019-2020 | |
| Pfizer INC. | $40.00 | 2021-2025 | |
| Biomerieux INC | $40.00 | 2023 | Biofire Respiratory Panel 2.1 |
| Alexion Pharmaceuticals, INC. | $33.70 | 2019 | |
| Mallinckrodt Hospital Products INC. | $33.01 | 2022-2023 | Acthar |
| Paratek Pharmaceuticals, INC. | $30.12 | 2019 | |
| Nabriva Therapeutics, Plc | $29.40 | 2021 | |
| Csl Behring | $27.30 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $26.42 | 2019 | |
| Monaghan Medical Corporation | $21.00 | 2025 | Aerochamber |
| Genentech USA, INC. | $20.58 | 2019 | |
| United Therapeutics Corporation | $18.08 | 2021 | |
| Circassia INC. | $16.97 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.35 | 2021 | |
| Allergan, INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Nasir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.